Target Name: LPAR3
NCBI ID: G23566
Other Name(s): LPA receptor EDG7 | LPA3 | Endothelial cell differentiation gene 7 | LPAR3_HUMAN | Lysophosphatidic acid receptor Edg-7 | Endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 7 | Edg-7 | RP4-678I3 | Lysophosphatidic acid receptor 3 | lysophosphatidic acid receptor Edg-7 | LPA receptor 3 | EDG7 | lysophosphatidic acid receptor 3 | LPA-3 | endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 7 | LP-A3 | calcium-mobilizing lysophosphatidic acid receptor LP-A3 | Calcium-mobilizing lysophosphatidic acid receptor LP-A3 | endothelial cell differentiation gene 7 | HOFNH30 | GPCR

Discovering The LPA-Receptor EDG7: A Potential Drug Target for Bile Acid Transport and Metabolism

The liver is a vital organ that plays a crucial role in the body, responsible for filtering waste products, synthesizing hormones, and maintaining the body's chemical balance. The liver also produces more than 50% of the body's bile, which is essential for digestion. One of the critical proteins involved in this process is the liver-specific receptor, LPA-receptor EDG7. This protein is expressed in the liver and other organs, and its function is to regulate the movement of bile into the intestine.

The LPA-receptor EDG7 is a protein that is expressed in various tissues throughout the body, including the liver, spleen, pancreas, and small intestine. It is a member of the LPA-1 subfamily of the evolutionarily conserved G protein-coupled receptor ( GPCR) family. LPA-receptor EDG7 is known for its role in bile acid transport and metabolism, and for its potential as a drug target or biomarker.

Bioinformatics Analysis

The LPA-receptor EDG7 gene was first identified in the mouse gene database using bioinformatics analysis. The gene is located on chromosome 19 at position 362. The coding region for the LPA-receptor EDG7 protein is 1,284 amino acids long and has a calculated molecular weight of 17,414. The protein has a single transmembrane domain and an extracellular domain that is involved in interactions with other proteins.

Expression and Localization

LPA-receptor EDG7 is expressed in various tissues throughout the body, including the liver, spleen, pancreas, and small intestine. The protein is predominantly expressed in the liver, with a relatively low expression level in the other tissues. The liver is the primary site of LPA-receptor EDG7 expression, and the protein is predominantly localized to the liver sinusoids, which are specialized blood vessels that receive blood from the hepatic artery.

Function and Significance

LPA-receptor EDG7 is involved in the movement of bile acids into the intestine. Bile acids are produced by the liver and are then transported to the intestine for digestion and absorption. LPA-receptor EDG7 is essential for the efficient transport of bile acids into the intestine. intestine. When LPA-receptor EDG7 is activated, it triggers a signaling cascade that results in the release of bile acids into the intestine.

In addition to its role in bile acid transport, LPA-receptor EDG7 is also involved in the regulation of inflammation and metabolism. The protein has been shown to play a role in the regulation of immune cell function, and has been linked to the production of pro-inflammatory cytokines. LPA-receptor EDG7 has also been shown to play a role in the regulation of metabolism, particularly in the production of fatty acids.

Drug Target Potential

LPA-receptor EDG7 is a potential drug target due to its involvement in bile acid transport and metabolism. Many studies have suggested that inhibiting LPA-receptor EDG7 activity may be a useful strategy for treating various diseases, including liver disease, obesity, and metabolic disorders.

One approach to inhibiting LPA-receptor EDG7 activity is to target the protein directly. Several small molecules have been shown to be LPA-receptor EDG7 inhibitors, and have been tested in animal models of various diseases. For example, a compound called JS-2143 has been shown to be an LPA-receptor EDG7 inhibitor, and has been shown to protect against the development of liver cancer in animal models.

Another approach to inhibiting LPA-receptor EDG7 activity is to target the protein indirectly. Several genetic modifiers, such as CRISPR/Cas9

Protein Name: Lysophosphatidic Acid Receptor 3

Functions: Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer. Seems to be coupled to the G(i)/G(o) and G(q) families of heteromeric G proteins

More Common Targets

LPAR4 | LPAR5 | LPAR6 | LPCAT1 | LPCAT2 | LPCAT3 | LPCAT4 | LPGAT1 | LPIN1 | LPIN2 | LPIN3 | LPL | LPO | LPP | LPP-AS1 | LPP-AS2 | LPXN | LRAT | LRATD1 | LRATD2 | LRBA | LRCH1 | LRCH2 | LRCH3 | LRCH4 | LRCOL1 | LRFN1 | LRFN2 | LRFN3 | LRFN4 | LRFN5 | LRG1 | LRGUK | LRIF1 | LRIG1 | LRIG2 | LRIG2-DT | LRIG3 | LRIG3-DT | LRIT1 | LRIT2 | LRIT3 | LRMDA | LRP1 | LRP10 | LRP11 | LRP12 | LRP1B | LRP2 | LRP2BP | LRP3 | LRP4 | LRP4-AS1 | LRP5 | LRP5L | LRP6 | LRP8 | LRPAP1 | LRPPRC | LRR1 | LRRC1 | LRRC10 | LRRC10B | LRRC14 | LRRC14B | LRRC15 | LRRC17 | LRRC18 | LRRC19 | LRRC2 | LRRC2-AS1 | LRRC20 | LRRC23 | LRRC24 | LRRC25 | LRRC26 | LRRC27 | LRRC28 | LRRC3 | LRRC30 | LRRC31 | LRRC32 | LRRC34 | LRRC36 | LRRC37A | LRRC37A11P | LRRC37A14P | LRRC37A15P | LRRC37A16P | LRRC37A17P | LRRC37A2 | LRRC37A3 | LRRC37A4P | LRRC37A5P | LRRC37A6P | LRRC37A7P | LRRC37A9P | LRRC37B | LRRC37BP1 | LRRC38